Abbott Laboratories 2012 Annual Report Download - page 16

Download and view the complete annual report

Please find page 16 of the 2012 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 68

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68

Abbott Innovation
highlights
Xience Xpedition — Vascular iDesign — Vision Care
Vascular / Structural Heart
Abbott continues to develop next-
generation products for established
categories with breakthrough products
like Absorb, our transformational
bioresorbable device. Xience Xpedition
is our latest drug-eluting stent system.
Our MitraClip system, which is available
in a number of international markets and
is an investigational device in the United
States, is designed to repair a patient’s
leaking mitral heart valve.
Established Pharmaceuticals
Over the next several years, Abbott
expects to bring our branded generic
pharmaceuticals to broader patient
populations through registrations
across multiple geographies, as well
as launches of new brands, packaging
enhancements, and improved
formulations to enhance efficacy and
improve convenience.
Diagnostics
In diagnostics, Abbott’s new-product
pipeline is focused on innovations
designed to speed the process of
identifying disease and to identify which
patients are more likely to benefit from
a particular therapy. Abbott is developing
next-generation systems and tests, as
well as automation and information
solutions, that will help labs generate
better information more quickly than
ever before.
Duphaston — Established Pharmaceuticals
14
Abbott 2012 Annual Report